Non-peptide

Dasatinib + Quercetin

Also known as

D+Q · D plus Q senolytic · Sprycel + quercetin

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	D+Q combines the prescription cancer drug dasatinib with the plant flavonoid quercetin, usually in brief oral pulses.
Senolytic aim	The experimental aim is removing some senescent cells, which have stopped dividing. That does not establish rejuvenation or a healthy-aging regimen.

Notes

Dasatinib + Quercetin, or D+Q, pairs a leukemia drug with a plant flavonoid in experimental senolytic use. Longevity communities discuss brief oral pulses for healthier aging and recovery. Experiences range from claimed improvement to no change or feeling unwell; the combination has no established healthy-aging regimen.

Two separate oral ingredients. Dasatinib, including the brand Sprycel, is a prescription cancer drug. Quercetin is a plant compound sold in supplements. D+Q is a combination rather than a single ingredient or a peptide injection. DailyMed — Sprycel (dasatinib) prescribing information (Official context · Accessed 2026-09-30)

Senolytic means targeting senescent cells. These cells have stopped dividing and can contribute to inflammation. Removing some is the experimental aim; clearing cells does not guarantee rejuvenation. Hickson et al. — Senolytics decrease senescent cells in humans: preliminary diabetic kidney disease trial (Official context · Accessed 2026-09-30)

Source context — DailyMed — Sprycel (dasatinib) prescribing information: Approved oncology drug information, not approval or safety validation for healthy-aging D+Q; risk frequencies in cancer treatment are not transplanted to short pulses.

Source context — Hickson et al. — Senolytics decrease senescent cells in humans: preliminary diabetic kidney disease trial: Small open-label condition-specific study. Abstract/selected figure captions inspected, not full-text protocol; no healthy-user lifespan benefit or measured felt duration.

What people notice

Joint comfort	One user credited D+Q alongside rapamycin with major knee improvement and renewed trail running over two years. The account cannot show which agent helped.
No noticeable change	Another user reported no noticeable effect after more than two years of intermittent D+Q.
Feeling unwell	Separate accounts describe nausea, feverishness, chills, headache, tiredness or brain fog. These are not proof of senescent-cell die-off.

Notes

Joint comfort and returning to activity. Todd on Rapamycin.news credits D+Q alongside rapamycin with major knee improvement and renewed trail running over two years. This is one combined-treatment account, not evidence that D+Q alone repairs cartilage. Rapamycin.news — Has anyone used dasatinib+quercetin as a senolytic? (Personal report · Accessed 2026-09-30)

Improvement does not settle which agent helped. Replies challenge Todd's combined-treatment attribution; he declines to stop an agent to isolate it. He reports later adding taurine and GlyNAC after the initial improvement, so those additions do not explain that earlier period. Rapamycin.news — Has anyone used dasatinib+quercetin as a senolytic? (Personal report · Accessed 2026-09-30)

No change after years is part of the picture. George reports no noticeable effect after more than two years of intermittent D+Q. This counters a guaranteed-benefit story without proving there was no biological effect. Rapamycin.news — Has anyone used dasatinib+quercetin as a senolytic? (Personal report · Accessed 2026-09-30)

One account: nausea after 3–4 hours. The Age Reversal contributor later described evening feverishness, chills and headache. This is adverse-symptom onset, not demonstrated senolytic benefit. Age Reversal Forum — Details of dasatinib + quercetin study (Personal report · Accessed 2026-09-30)

Another account: fatigue and brain fog still present at day five. The same Age Reversal contributor continued to feel unwell after the initial nausea and feverishness. A short drug half-life does not promise a short symptom window. Age Reversal Forum — Details of dasatinib + quercetin study (Personal report · Accessed 2026-09-30)

Feeling sick is not proof that it worked. Nausea, headache, fatigue, feverishness and mood shifts are not proof of senescent-cell die-off. Chest pain, breathing difficulty, serious bleeding, severe allergy, new neurological symptoms or dangerous blood-pressure or blood-sugar changes need medical attention. Age Reversal Forum — Details of dasatinib + quercetin study (Personal report · Accessed 2026-09-30) · DailyMed — Sprycel (dasatinib) prescribing information (Official context · Accessed 2026-09-30)

Source context — Rapamycin.news — Has anyone used dasatinib+quercetin as a senolytic?: Self-reported identities, products and outcomes; co-treatment confounding. Overlapping base-thread and /17 views are one source and the same users, not independent reports.

Source context — Age Reversal Forum — Details of dasatinib + quercetin study: One uncontrolled account; exact post date not exposed in readable view. Author's die-off explanation is unverified. Other reply pages not exhaustively inspected.

Doses people talk about

Research-inspired copies	About 100 mg dasatinib plus 1,000–1,250 mg quercetin daily on the same 2–3 oral days. Protocols differ; no longevity dose is validated here.
Separate forum amounts	Two users report on-day totals of 100 mg D with 1,200 mg Q, or 100 mg D with 1,500 mg Q. Dose splitting is unstated.
Other forms and outliers	One stack used 120 mg D with 1,200 mg quercetin phytosome per treatment; another account reports one 200 mg D plus 2,000 mg Q administration. Phytosome mg are not plain-quercetin equivalents.

Notes

Copied research amounts: about 100 mg D daily, with 1000–1250 mg Q daily. Research-inspired community copies describe these daily totals on the same 2–3 oral days. The quercetin range reflects different protocols, not an interchangeable target or a validated longevity dose.

Two forum examples: 100 mg D with 1200 mg Q; 100 mg D with 1500 mg Q. These are separate users' reported on-day totals, with different calendars and outcomes; dose splitting is unstated. Rapamycin.news — Has anyone used dasatinib+quercetin as a senolytic? (Personal report · Accessed 2026-09-30)

Other individual amounts stay separate. Fafner55 describes 120 mg D with 1200 mg quercetin phytosome per treatment alongside fisetin and honokiol. An Age Reversal contributor reports one oral administration of 200 mg D with 2000 mg Q. These are reports, not recommendations. Longecity — Dasatinib + Quercetin; please share dosing info (Personal report · Accessed 2026-09-30) · Age Reversal Forum — Details of dasatinib + quercetin study (Personal report · Accessed 2026-09-30)

Quercetin forms matter. The Longecity account uses quercetin phytosome. Its product milligrams are not automatically equivalent to plain quercetin powder, capsules or another enhanced formulation. Longecity — Dasatinib + Quercetin; please share dosing info (Personal report · Accessed 2026-09-30)

Source context — Longecity — Dasatinib + Quercetin; please share dosing info: One author's stack, unverified products; same-author follow-up is not another report. No blood work supported his liver concern. Advice and dose scaling are not adopted.

Half-life, onset & duration

Felt onset	One user reported nausea after 3–4 hours; another a mild rush around three hours followed by tiredness. Dependable benefit onset is not established.
Felt duration	One mixed-stack account reported about a day of fatigue; another still had fatigue and brain fog at day five. Duration of benefit is not established.
Half-life	Dasatinib's labeled adult terminal half-life is 3–5 hours. A circulated quercetin estimate of about 3.5 hours lacks enough formulation detail to apply across products; there is no single D+Q clock.

Notes

A different account: a rush after roughly 3 hours. Reddit contributor earonesty reported no early change, then a mild buzz and marked tiredness that night. This does not establish a typical stimulant effect or cell clearance. Reddit r/longevity — Results from self tests of Quercetin and Dasatinib? (Personal report · Accessed 2026-09-30)

Benefit onset remains unclear. Months-long self-logs and accounts of no change do not provide a dependable hour or day when healthier-aging benefits begin.

Mild fatigue: about one day in one stack account. Fafner55 reports this with several compounds taken together. It cannot identify which ingredient caused the fatigue or measure a D+Q benefit window. Longecity — Dasatinib + Quercetin; please share dosing info (Personal report · Accessed 2026-09-30)

No established duration of benefit. Long gaps between pulses are not evidence that a dose keeps working throughout that interval. No noticeable effect and months-long improvement stories answer different questions.

Revised 9/2026; indications, warnings 5.1–5.11, interactions section 7, pregnancy/lactation section 8, clinical pharmacology 12.3 (adult terminal half-life 3–5 h). DailyMed — Sprycel (dasatinib) prescribing information (Official context · Accessed 2026-09-30)

Dasatinib: 3–5 hours is a circulated label figure. A Rapamycin.news explainer repeats this clinical drug-information figure. It is not user-measured elimination or a D+Q blend clock. Rapamycin.news — Zombie Cell Hunters Fail to Resurrection Aged Immune Response in Flu Challenge (Secondhand community claim · Accessed 2026-09-30)

Quercetin: about 3.5 hours is also claimed. The same explainer acknowledges formulation variability but gives insufficient measurement detail for applying this across products. Neither estimate establishes complete clearance or symptom duration. Rapamycin.news — Zombie Cell Hunters Fail to Resurrection Aged Immune Response in Flu Challenge (Secondhand community claim · Accessed 2026-09-30)

Source context — Reddit r/longevity — Results from self tests of Quercetin and Dasatinib?: Only a two-day account, no verified products, tests or later follow-up; shorthand 120/2000 D/Q lacks explicit units and is therefore not used as a new numeric dose. Relative timestamps do not establish exact publication dates.

Source context — Rapamycin.news — Zombie Cell Hunters Fail to Resurrection Aged Immune Response in Flu Challenge: Community research explainer, not first-person timing data. Several strong scientific and safety claims are unsupported or overconfident; mouse-to-human arithmetic, complete-clearance and weeks-of-effect claims are not adopted.

Cycles people discuss

Short pulses	Community calendars copy 2–3 consecutive on-days with monthly or quarterly repeats, followed by weeks or months off. These are not universally tested schedules.
Different calendars	One user reports two days every other month. Another reports three consecutive days for three weeks, repeated every 4–5 months; the weekly breaks are unclear.
Break length	No safe reset interval or preferred morning/evening slot is established. Long gaps do not show that benefits last throughout them.

Notes

Brief on-days, then weeks or months off. Community calendars include 2–3 consecutive oral days with monthly or quarterly repeats. Cost and caution also shape the gaps; this is not a universally tested schedule.

Every-other-month and 4–5-month calendars both appear. Todd describes two consecutive days every other month. George describes three consecutive days for three weeks, repeated every 4–5 months; the post does not clearly spell out the weekly breaks. Rapamycin.news — Has anyone used dasatinib+quercetin as a senolytic? (Personal report · Accessed 2026-09-30)

No preferred clock time or proven reset interval. Older discussion considers side effects, training and sleep, without establishing morning versus evening superiority or a safe break length.

Stacks

Rapamycin	The knee-improvement account used D+Q alongside rapamycin and did not isolate their effects. Taurine and GlyNAC were added after the initial improvement.
Fisetin and honokiol	One quercetin-phytosome account included fisetin and honokiol, then reduced plant-compound amounts after greater fatigue.

Notes

Changing a stack can change tolerability. Fafner55 reduced plant-compound amounts after greater fatigue. His concern about liver strain was not backed by blood tests; fever, diarrhea and skin sloughing were things he monitored, not all symptoms he experienced. Longecity — Dasatinib + Quercetin; please share dosing info (Personal report · Accessed 2026-09-30)

Watch for

Serious drug risks	Dasatinib's label warns about low blood-cell counts, bleeding, fluid around the lungs, heart problems and liver injury. Brief pulses are not a safety guarantee.
Interactions and pregnancy	Blood thinners, grapefruit, CYP3A4-affecting drugs and acid reducers can change risk or exposure. Fetal-harm and breastfeeding warnings remain relevant.
Adverse symptoms	Sickness does not demonstrate successful cell clearance. Chest pain, breathing difficulty, serious bleeding, severe allergy or new neurological symptoms need medical attention.
Animal safety concern	A 2026 study found myelin damage in young and aged mice given D+Q. It raises concern without measuring human injury rates; repeated-pulse safety remains uncertain.

Notes

Dasatinib carries serious drug risks. Its label warns about low blood-cell counts, bleeding, fluid around the lungs, heart problems and liver injury. Cancer-treatment risk rates differ from intermittent use; brief exposure is not a safety guarantee. DailyMed — Sprycel (dasatinib) prescribing information (Official context · Accessed 2026-09-30)

Interactions and pregnancy matter. Blood thinners, grapefruit, drugs affecting the CYP3A4 drug-processing enzyme, and acid-reducing medicines can change risk or exposure. Dasatinib can harm a fetus; breastfeeding also carries a labeled warning. A supplement stack is not an interaction check. DailyMed — Sprycel (dasatinib) prescribing information (Official context · Accessed 2026-09-30)

A 2026 mouse finding adds caution. Lombardo and colleagues found damage to myelin, the insulating covering around nerve fibers, in young and aged mice given D+Q. This is animal evidence, not a measured rate of brain injury in human users. Lombardo et al. — Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum (Animal context · Accessed 2026-09-30)

Long-term self-experiment safety remains uncertain. Unverified preparations and stacks complicate identity and adverse-effect attribution. Lack of immediate symptoms or reassuring routine blood tests does not establish repeated-pulse safety.

Source context — Lombardo et al. — Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum: Primary paper accessed through a publicly linked forum mirror after PNAS/PMC access problems. Mouse and rat-cell experiments; no human risk incidence. Only selected pages inspected.

Full notes

What D+Q is

Two separate oral ingredients. Dasatinib, including the brand Sprycel, is a prescription cancer drug. Quercetin is a plant compound sold in supplements. D+Q is a combination rather than a single ingredient or a peptide injection. Official context Community
Senolytic means targeting senescent cells. These cells have stopped dividing and can contribute to inflammation. Removing some is the experimental aim; clearing cells does not guarantee rejuvenation. Official context
Quercetin forms matter. The Longecity account uses quercetin phytosome. Its product milligrams are not automatically equivalent to plain quercetin powder, capsules or another enhanced formulation. Personal report Community

Why people look it up

Joint comfort and returning to activity. Todd on Rapamycin.news credits D+Q alongside rapamycin with major knee improvement and renewed trail running over two years. This is one combined-treatment account, not evidence that D+Q alone repairs cartilage. Personal report
Healthier aging rather than a workout boost. Community goals include energy, recovery, bone health and cognition. Earlier accounts judge changes over months, sometimes following glucose, cholesterol or inflammation blood tests. Those goals and measurements do not establish longer life or better cognition. Community
A small human signal, with a narrow meaning. A nine-person diabetic-kidney-disease pilot found reductions in tissue markers associated with senescent cells after a brief oral course. That supports continued investigation, not proven healthspan benefit for healthy people. Official context

Doses people discuss

Copied research amounts: about 100 mg D daily, with 1000–1250 mg Q daily. Research-inspired community copies describe these daily totals on the same 2–3 oral days. The quercetin range reflects different protocols, not an interchangeable target or a validated longevity dose. Community
Two forum examples: 100 mg D with 1200 mg Q; 100 mg D with 1500 mg Q. These are separate users' reported on-day totals, with different calendars and outcomes; dose splitting is unstated. Personal report
Other individual amounts stay separate. Fafner55 describes 120 mg D with 1200 mg quercetin phytosome per treatment alongside fisetin and honokiol. An Age Reversal contributor reports one oral administration of 200 mg D with 2000 mg Q. These are reports, not recommendations. Personal report Personal report

Half-life discussed online

Dasatinib: 3–5 hours is a circulated label figure. A Rapamycin.news explainer repeats this clinical drug-information figure. It is not user-measured elimination or a D+Q blend clock. Rapamycin.news
Quercetin: about 3.5 hours is also claimed. The same explainer acknowledges formulation variability but gives insufficient measurement detail for applying this across products. Neither estimate establishes complete clearance or symptom duration. Rapamycin.news

When people notice something

One account: nausea after 3–4 hours. The Age Reversal contributor later described evening feverishness, chills and headache. This is adverse-symptom onset, not demonstrated senolytic benefit. Personal report
A different account: a rush after roughly 3 hours. Reddit contributor earonesty reported no early change, then a mild buzz and marked tiredness that night. This does not establish a typical stimulant effect or cell clearance. Personal report
Benefit onset remains unclear. Months-long self-logs and accounts of no change do not provide a dependable hour or day when healthier-aging benefits begin. Community

How long effects seem to last

Mild fatigue: about one day in one stack account. Fafner55 reports this with several compounds taken together. It cannot identify which ingredient caused the fatigue or measure a D+Q benefit window. Personal report
Another account: fatigue and brain fog still present at day five. The same Age Reversal contributor continued to feel unwell after the initial nausea and feverishness. A short drug half-life does not promise a short symptom window. Personal report
No established duration of benefit. Long gaps between pulses are not evidence that a dose keeps working throughout that interval. No noticeable effect and months-long improvement stories answer different questions. Community

Pulses and breaks

Brief on-days, then weeks or months off. Community calendars include 2–3 consecutive oral days with monthly or quarterly repeats. Cost and caution also shape the gaps; this is not a universally tested schedule. Community
Every-other-month and 4–5-month calendars both appear. Todd describes two consecutive days every other month. George describes three consecutive days for three weeks, repeated every 4–5 months; the post does not clearly spell out the weekly breaks. Personal report
No preferred clock time or proven reset interval. Older discussion considers side effects, training and sleep, without establishing morning versus evening superiority or a safe break length. Community

Cautions worth understanding

Dasatinib carries serious drug risks. Its label warns about low blood-cell counts, bleeding, fluid around the lungs, heart problems and liver injury. Cancer-treatment risk rates differ from intermittent use; brief exposure is not a safety guarantee. Official context
Interactions and pregnancy matter. Blood thinners, grapefruit, drugs affecting the CYP3A4 drug-processing enzyme, and acid-reducing medicines can change risk or exposure. Dasatinib can harm a fetus; breastfeeding also carries a labeled warning. A supplement stack is not an interaction check. Official context
Feeling sick is not proof that it worked. Nausea, headache, fatigue, feverishness and mood shifts are not proof of senescent-cell die-off. Chest pain, breathing difficulty, serious bleeding, severe allergy, new neurological symptoms or dangerous blood-pressure or blood-sugar changes need medical attention. Community Personal report Official context
A 2026 mouse finding adds caution. Lombardo and colleagues found damage to myelin, the insulating covering around nerve fibers, in young and aged mice given D+Q. This is animal evidence, not a measured rate of brain injury in human users. Animal context
Long-term self-experiment safety remains uncertain. Unverified preparations and stacks complicate identity and adverse-effect attribution. Lack of immediate symptoms or reassuring routine blood tests does not establish repeated-pulse safety. Community

What community accounts add

No change after years is part of the picture. George reports no noticeable effect after more than two years of intermittent D+Q. This counters a guaranteed-benefit story without proving there was no biological effect. Personal report
Improvement does not settle which agent helped. Replies challenge Todd's combined-treatment attribution; he declines to stop an agent to isolate it. He reports later adding taurine and GlyNAC after the initial improvement, so those additions do not explain that earlier period. Personal report
Changing a stack can change tolerability. Fafner55 reduced plant-compound amounts after greater fatigue. His concern about liver strain was not backed by blood tests; fever, diarrhea and skin sloughing were things he monitored, not all symptoms he experienced. Personal report
Exercise and sleep can be disrupted. The Reddit user described sleeping ten hours and temporarily avoiding exercise. That disruption is one person's experience, not a validated recovery requirement. Personal report
New safety discussion is unsettled. The March 2026 Rapamycin.news thread questions whether possible benefits justify the mouse myelin concern. Complaints about supplement-only activators or unspecified cocktails do not tell us how D+Q itself feels. Rapamycin.news
Fisetin and blood tests do not isolate D+Q. Fisetin appears as an alternative or add-on; rapamycin and other longevity agents recur in stacks. Changes in pain, energy or an inflammation test cannot identify the responsible ingredient or directly count senescent cells. Community Community